Barbara Crossley
@crossb
oddball mix of enthusiasms -poetry, theatre, bronchiectasis
ID: 20662053
12-02-2009 08:23:39
946 Tweet
237 Takipçi
688 Takip Edilen
Join us for a free EMBARC webinar on airway clearance and pulmonary rehabilitation 👇🫁 ERS_physios ERS_Assembly9 ACPRC The London ACPRC Hub Love Your Lungs King's Physiotherapy School of Life Course & Population Sciences
New paper from EMBARC Diagnostic delay and access to care in bronchiectasis A survey of 760 patients from 40 countries 40% of patients wait 5 years+ for a diagnosis and 25% wait >10 years from symptom onset led by Dr Arietta Spinou Michal Shteinberg erj.ersjournals.com/content/erj/ea…
Tomorrow is World Bronchiectasis Day! Join us for a special webinar- ask you questions and get answers from real experts on the condition including מיכל שטיינברג Stefano Aliberti Barbara Crossley and many more I'll be behind the scenes answering as many questions as i can!
Bronchiectasis is a heterogeneous disease. if we want personalised medicine, we need BIOMARKERS to guide treatment Explore the pathophysiology of bronchiectasis by checking out our latest paper from Emma Johnson and Merete Long err.ersjournals.com/content/errev/…
Patient perspective represented by Barbara Crossley and her colleague from Greece European Lung Foundation EMBARC
Its time to shift the paradigm in bronchiectasis Thinking about bronchiectasis as an inflammatory disease means - earlier intervention - focus on non-antibiotic treatments - clinicians and scientists working together - Pipeline of new anti-inflammatory treatments Merete Long
For most of the past 3 decades, bronchiectasis has been treated as an infectious disease. A new Review in The Lancet Respiratory Medicine argues that bronchiectasis is primarily a chronic inflammatory disease and introduces a novel concept of disease activity: hubs.li/Q02FqqBl0